Edmonton International Airport has been chosen as the exclusive location to trial a new COVID-19 test that can produce results in seconds.
September 24, 2020 (Edmonton, AB) – Edmonton International Airport has been chosen as the exclusive location to trial a new COVID-19 test that can produce results in seconds.
In partnership with GLC Medical (GLCM) Inc., a subsidiary of Graphene Leaders Canada (GLC) Inc., an Edmonton-based company, EIA will host clinical trials of this new technology that has the potential to have global implications for COVID-19 testing. This test is conducted with a handheld unit that takes a saliva sample from a person and is expected to tell if someone has COVID-19 in under 1-minute, compared to other tests with longer laboratory-based waiting periods for results. This test promises many advantages from its ease of use to the elimination of the nasal swab to direct virus detection. This kind of test will help address the need for a 14-day quarantine period in Canada and potentially other international quarantine restrictions. By removing or reducing this barrier, it can help travelers feel safer in returning to travel.
GLC Medical (GLCM) Inc. is headquartered in the Edmonton Research Park and has garnered international attention for the development of this test, which is still undergoing clinical testing as part of the regulatory approval process with health authorities. As an airport, EIA understands working with governments and within a regulated structure. With secure and safe facilities and a consistent flow of passengers, it’s one reason an airport is an ideal place to start testing the trial phase of this new COVID-19 rapid test.
“We all want travel to get back to normal and a rapid COVID-19 test will accelerate this return while enhancing passenger confidence in the safety of our industry. While we have seen some growth in recent months, our passenger numbers during COVID-19 continue to remain low and a test like this is crucial to our future. All airlines, airports and the whole travel and hospitality sector are looking for this solution. If EIA can play a role in bringing new technology and science forward by partnering with experts like GLC that’s exactly what we’re going to do. This is an exciting opportunity for all of us.”
-Tom Ruth, CEO and President, Edmonton International Airport
“We are very excited to offer the world a graphene-enhanced rapid solution in COVID-19 virus detection. The opportunity to collaborate with EIA, a world-respected airport authority, to enable travel and to bring families back together is very rewarding for us. This graphene-enhanced rapid test demonstrates the power of graphene innovation to overcome the challenges of COVID-19. GLC is proud to be a part of EIA’s initiative in setting the global standard in safety and reliability for their travelers.”
-Donna Mandau, President & CEO, Graphene Leaders Canada (GLC) Inc. / GLC Medical (GLCM) Inc.
How the test works:
• The person being tested provides a saliva sample into the testing unit;
• The graphene surface inside the testing unit is designed to bond to the spike protein in the virus;
• This binding event changes the electronic characteristics of the graphene, and this measurable change is what is used to determine if a person is infected or not;
• The device will show a red or green light in under 1-minute to indicate if a person is virus free or not;
• The test is not required to be administered by a medical professional and with training can be
administered by anyone, similar to how basic first aid training is done.
The next step is to bring this test and GLC to EIA and establish a safe and secure test site. Details about the testing and the process will be shared in the coming weeks. A start date has not been determined, but once it begins, the clinical trial will last several weeks over this fall. This trial phase will help GLC Medical secure regulatory approval and certification for its test from Health Canada and other regulatory bodies, including in the United States and other areas of the world.
As a not-for-profit corporation, EIA works to attract investment and jobs to the Edmonton Metro Region and support local innovation. Airports connect global communities and create opportunities for people and business. The partnership with GLC Medical has tremendous opportunities to impact many industries beyond just the travel industry. EIA is focused on safety and security as its number one core value and creating a safe passenger experience at the airport is a priority. The EIA Ready program focuses not only on enhanced cleaning but also seeking out and adopting new innovations and technologies to help passengers feel comfortable in the airport and with travel overall. The recent announcement of EIA being accredited by Airports Council International (ACI) with the airport health certification is yet another example of how EIA is putting safety and security as a top priority in creating a safe airport. Visit www.flyeia.com/ready for more information.
About Edmonton International Airport
Edmonton International Airport is a self-funded, not-for-profit corporation whose mandate is to drive economic prosperity for the Edmonton Region. EIA is Canada’s fifth-busiest airport by passenger traffic and the largest major Canadian airport by land area. EIA offers non-stop connections to destinations across Canada, the US, Mexico, the Caribbean and Europe. EIA is a major economic driver, with an economic output of over $3.2 billion, supporting over 26000 jobs. For more information, please visit: flyeia.com, follow @flyeia on Twitter, Instagram, LinkedIn or Facebook.
About GLC
Graphene Leaders Canada (GLC) Inc. is a Canadian technology company producing high quality, high purity graphene nanomaterials which functions as a platform technology with the ability to add value across numerous applications. Graphene Leaders Canada Inc. is focused to work with industry to develop solutions by integrating the graphene to develop new innovative products. GLC’s tag line is “Making Great Products Even Greater”.
GLC Medical (GLCM) Inc. is a subsidiary of GLC Inc. and offers graphene solutions in the medical industry leveraging our material science expertise in working with high quality graphene and developing products and solutions to serve the betterment of People and Planet.
Media Contact:
Darrell Winwood
EIA Corporate Communications
c: 587-338-4454
e: dwinwood@flyeia.com
Donna Mandau
President and CEO
Graphene Leaders Canada (GLC) Inc.
GLC Medical (GLCM) Inc.
c: 780-984-4737
e: dmandau@glcplus.com